Zydus Lifesciences Limited, along with its subsidiaries/affiliates, has received final approval from the United States Food and Drug Administration (USFDA) for Sugammadex Injection, available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. This medication is used to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult surgical patients. It will be manufactured at Zydus’ injectable manufacturing facility in Jarod, India.
The annual sales of Sugammadex Injection in the United States amounted to USD 986 million as of August 2023 (according to IQVIA MAT Aug 2023). Zydus now boasts a total of 381 approvals and has submitted over 444 ANDAs since the initiation of the filing process in FY 2003-04.
On Friday, the shares of Zydus Lifesciences closed flat at Rs. 605, showing a minimal decrease of 0.01% on the NSE.